

CITATION REPORT

List of articles citing

The Science Behind Biosimilars: Entering a New Era of Biologic Therapy

DOI: 10.1002/art.40388

Arthritis and Rheumatology, 2018, 70, 334-344.

Source: <https://exaly.com/paper-pdf/69081998/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
30	Editorial: The American College of Rheumatology White Paper on Biosimilars: It Isn't All White-There Is Some Gray and Black. <i>Arthritis and Rheumatology</i> , 2018 , 70, 323-325	9.5	13
29	Focus on biosimilar etanercept - bioequivalence and interchangeability. <i>Biologics: Targets and Therapy</i> , 2018 , 12, 87-95	4.4	11
28	Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext). <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1097-1105	5.4	9
27	Biosimilars for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 1195-1203	5.2	1
26	Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2019 , 17, 67	3.5	5
25	Are There Benefits and Risks to Biosimilars from a Patient Perspective?. <i>Rheumatic Disease Clinics of North America</i> , 2019 , 45, 465-476	2.4	3
24	Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review. <i>Advances in Therapy</i> , 2019 , 36, 1851-1877	4.1	14
23	Tapering biologic therapy for people with rheumatoid arthritis in remission: A review of patient perspectives and associated clinical evidence. <i>Musculoskeletal Care</i> , 2019 , 17, 161-169	1.6	4
22	Pharmacologic Management of Rheumatoid Arthritis. <i>Orthopaedic Nursing</i> , 2019 , 38, 390-395	0.9	
21	Bioequivalence studies with anti-TNF biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1031-1043	5.1	2
20	Rheumatoid Arthritis. <i>Annals of Internal Medicine</i> , 2019 , 170, ITC1-ITC16	8	193
19	Scrutinizing the Frustrating Cost of Drugs: How Rebates and Step Therapy Inflate Medicare Part D Prices-and Possible Reforms. <i>Arthritis and Rheumatology</i> , 2020 , 72, 203-205	9.5	
18	Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. <i>Scientific Reports</i> , 2020 , 10, 16178	4.9	5
17	The Importance of Countering Biosimilar Disparagement and Misinformation. <i>BioDrugs</i> , 2020 , 34, 407-414	4.9	13
16	Biosimilars in rheumatic diseases. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13709	2.9	
15	decoction attenuates bone erosion in rats that have collagen-induced arthritis via modulating NF- κ B signalling to suppress osteoclastogenesis. <i>Pharmaceutical Biology</i> , 2021 , 59, 262-274	3.8	3
14	Emerging B-Cell Therapies in Systemic Lupus Erythematosus. <i>Therapeutics and Clinical Risk Management</i> , 2021 , 17, 39-54	2.9	12

13	Healthcare system conversion to a biosimilar: Trials and tribulations. <i>American Journal of Health-System Pharmacy</i> , 2021 ,	2.2	
12	OBSIDIAN - real world evidence of Originator to BioSimilar Drug switch in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021 ,	3.9	3
11	Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?. <i>BioDrugs</i> , 2020 , 34, 723-732	7.9	4
10	Biosimilars: Exploring the History, Science, and Progress. <i>Clinical Journal of Oncology Nursing</i> , 2018 , 22, 5-12	1.1	3
9	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. <i>Drugs</i> , 2021 , 81, 1859-1879	1.7	3
8	2018 Position Paper on Biosimilars of the Greek Rheumatology Society and Professional Association of Greek Rheumatologists. <i>Mediterranean Journal of Rheumatology</i> , 2019 , 30, 82-83	1.4	
7	Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2019 , 57, 46-55	0.9	3
6	A Systems Immunology Approach Identifies Cytokine-Induced STAT Signaling Pathways Critical to Rheumatoid Arthritis Disease Activity and Treatment Response.		
5	Rheumatic Diseases and Biosimilars: Evidence about Switch from Originators to Biosimilars in the Real Life.		
4	Biosimilar approval and checkpoints. <i>Journal of Preventive Medicine and Holistic Health</i> , 2021 , 7, 141-145		
3	Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients'satisfaction: a cross-sectional survey by patient organisations.. <i>BMJ Open</i> , 2022 , 12, e050949	3	0
2	Prescriber Perspectives on Biosimilar Adoption and Potential Role of Clinical Pharmacology: A Workshop Summary.		1
1	Safety and Effectiveness of Multiple Switching Between Originators and Biosimilars: Literature Review and Status Report on Interchangeability.		0